Why It’s Illegal to Call a Drug “Stroebenazoline”
Credibility score: 69/100 — Mostly Credible. Mixed credibility - some claims are solid, others need verification.
BSmeter analyzed "Why It’s Illegal to Call a Drug “Stroebenazoline”" and rated it 69/100 for credibility (a BS score of 31/100 — mostly credible), on 2026-09-20. Its weakest claim — "Claims 'lookalike soundalike' drugs cause 'at least a death a day' and 'million injuries a year' — then calls it 'life and death.' 💀" — scored 45/100 and was flagged as emotional button. 20 claims were checked against the video transcript. Scores are produced by BSmeter's AI analysis of the transcript, not independent human verification.
Of 20 claims analyzed: 0 scored under 40, 4 between 40 and 69, and 16 at 70 or above.
Claims analyzed
Video opens with a highlight reel preview of drug naming complexities. — Just Vibes (50/100)
At 0:00
A rapid-fire list of drug names and a quick setup for the 'complex process' of naming them. It's just setting the stage, no claims yet. 😈
Why this score: This is a typical video intro, quickly listing examples and hinting at the topic's complexity without making any specific, verifiable claims. It's pure setup, designed to hook the viewer.
Original quote: “Hello, welcome to the pharmacy. We have Zeljans and Zepbound and Cortef and Ogan, Omva and Limyv and yes, ibuprofen. [music] What we don't have is BVeline, Flexipo or Novo Rapid because [music] you're not allowed to name drugs. That turns out, while I thought drugs got their names from something…”
Sets up a dramatic reveal about drug names — then just states a fact. 😈 — No Frame (75/100)
At 0:40
He's building up the mystery, but the 'three names' thing is just how it works. No trick here, just a bit of theater. 🎭
Why this score: The speaker uses evocative language ('mad as a hatter,' 'holiday games') to introduce a seemingly complex topic. However, the claim that drugs have three different names (compound, generic, proprietary) is a straightforward description of pharmaceutical naming conventions, not a hidden truth or a manipulative frame. It's a setup for explanation, not deception.
Original quote: “It isn't just one of your holiday games. You may think at first I'm as mad as a hatter when I tell you a drug must have three different names.”
Claims 'lookalike soundalike' drugs cause 'at least a death a day' and 'million injuries a year' — then calls it 'life and death.' 💀 — Emotional Button (45/100)
At 1:14
He's hitting you with a 'death a day' stat from the WHO to make drug naming sound like a constant crisis. It's a real problem, but the framing is pure drama. 🔥
Why this score: The speaker uses a statistic attributed to the WHO ('at least a death a day and over a million injuries a year' from LASA errors) to emphasize the gravity of drug naming. While the issue of medication errors due to similar names is a serious concern, framing it as 'a matter of life and death' immediately after citing such a stark number is designed to evoke a strong emotional response (fear/urgency) rather than purely inform. It's not false, but it's certainly pushing an emotional button to underscore the importance.
Original quote: “The generic and proprietary naming processes are meant to ensure that nobody's going to screw up and get or give the wrong medication because it has a bad name. So-called Lassa or lookalike soundike medications according to the WHO cause [music] at least a death a day and over a million injuries a…”
States there are 'about 600' drug stems, then gives examples. 😈 — No Frame (75/100)
At 1:43
He's just laying out the rules for drug naming. No hidden agenda, just explaining the system. 📝
Why this score: The speaker is explaining the system of generic drug naming, specifically the use of 'stems' to indicate a drug's class or function. The number 'about 600' for these stems, and the examples of '-conazole' for antifungals and '-triptyline' for antidepressants, are accurate descriptions of the INN (International Nonproprietary Name) system. This is straightforward informational content without any manipulative framing.
Original quote: “There are about 600 of them. The connissol ending means it's an antifungal. Tryptalene means anti-depressant.”
Claims initial syllables are 'just sounds' for uniqueness, not scientific meaning. 😈 — No Frame (75/100)
At 1:52
He's pulling back the curtain on how these names are made. It's not always deep science, just practical naming. 💡
Why this score: The speaker explains that while drug stems have meaning, the initial syllables of a generic name are often chosen for phonetic reasons—to be unique, pronounceable, and globally usable—rather than having inherent scientific significance. This is an accurate insight into the practical considerations of drug nomenclature, aiming for clarity and distinctiveness to prevent errors. It's a factual explanation of the process.
Original quote: “The first few syllables might seem to have some scientific meaning, but usually they don't. They're kind of just sounds picked to make your drug name unique, unmistakable, and usable [music] around the world.”
Drug names too long: six syllables when five is max. That's a rule, not a suggestion. 😈 — No Frame (75/100)
At 2:36
He's just laying out the rules for drug naming — no tricks here, just the cold, hard facts of bureaucracy. 📜
Why this score: The speaker is explaining a specific regulatory guideline for drug nomenclature, stating that generic names should ideally be two syllables and no more than five. His proposed name 'Half as Interesting as a leen' has six syllables, violating this rule. This is a straightforward explanation of a constraint.
Original quote: “problem, it's too long. Half as Interesting as a leen has six syllables before the prefix [music] and generic names should have no more than five. ideally only two.”
Bad letters for drug names: H, K, J, W, Y are out. Global reach, global rules. 🌍 — No Frame (75/100)
At 2:44
More rules for drug naming, this time about global pronunciation. It's a practical constraint, not a conspiracy. 🗣️
Why this score: The speaker is detailing another practical rule for generic drug names: avoiding letters that are silent or non-existent in various non-English languages to ensure global usability and clarity. This is a logical and verifiable naming convention in the pharmaceutical industry.
Original quote: “ideally only two. Second, it starts with a bad letter. Generic drug names these days get used all around the world. So letters that are silent or non-existent in one or another non-English language like H, K, J, W, and Y don't fly.”
Can't name a drug after his channel: 'Half as Interesting' is out. Also, mixing up 'bowl' and 'bol' could lead to anabolic steroids instead of decongestants. 💀 — No Frame (75/100)
At 2:58
He's explaining the very real, very dangerous problem of sound-alike drug names. It's not a joke when someone gets the wrong meds. 💊
Why this score: The speaker highlights two critical reasons for name rejection: avoiding self-promotion (generic names are public domain) and preventing sound-alike/look-alike errors (SALAD) that could lead to dangerous medication mix-ups. This is a fundamental safety principle in pharmacology, and his example of 'Half as Interesting a bowl' versus 'Half as Interesting a bol' (anabolic steroid) clearly illustrates the risk.
Original quote: “Half as Interesting is of course also the name of this channel. The generic drug name, which will be public domain for anyone to use, can't [music] promote my YouTube channel. Plus, imagine we developed another drug and call it half as interesting a bowl. Just a bit of miscommunication or bad…”
A 'laundry list' of forbidden letter combos and word parts. He's not wrong, the rules are endless. 📜 — No Frame (75/100)
At 3:29
He's just stating the sheer volume of naming restrictions. It's a bureaucratic nightmare, not a trick. 😈
Why this score: The speaker is describing the extensive and complex rules governing drug nomenclature, specifically mentioning a 'laundry list' of forbidden letter combinations and word parts. This is a known reality in pharmaceutical naming, reflecting the need for unique, safe, and globally pronounceable names.
Original quote: “Alas, there's a laundry list of nogo letter combinations and word parts, and each of those have at least [music] two violations.”
They use a tool called 'PA' to score name similarity. Sounds like a real thing, but no details. 🤷♂️ — Anonymous Authority (45/100)
At 3:44
He mentions a tool called 'PA' without explaining what it is. A name and no context is just a whisper. 👻
Why this score: The speaker refers to a tool called 'PA' for scoring name similarity without providing any further details or context about what 'PA' stands for, how it works, or its official designation. While such tools likely exist, the lack of specifics makes this an anonymous authority claim.
Original quote: “which they test using a tool called PA to score for how similar my name is to anything else they have on record.”
Brand names skip WHO/Eucon Council. Different rules for different names. 🏷️ — No Frame (75/100)
At 4:13
He's correctly distinguishing between generic and brand name approval processes. Two different beasts, two different masters. ⚖️
Why this score: The speaker accurately differentiates between the approval processes for generic (INN) and brand/proprietary drug names. Generic names go through bodies like the WHO and INN Programme (Eucon Council is not a recognized body, likely a mispronunciation or conflation of INN Expert Group), while brand names are approved by national regulatory bodies like the FDA. This distinction is correct.
Original quote: “my brand or proprietary name. Unlike generic names, I won't have to push my names through the [music] Eucon Council or the WHO.”
FDA approves brand names, with a 'helpful 42-page guide.' And big pharma pays consultants half a million for names. 💸 — No Frame (75/100)
At 4:18
The FDA does have extensive guidelines, and pharma does spend insane money on branding. This is just the brutal truth of the industry. 💰
Why this score: The speaker correctly states that the FDA approves brand names and provides guidelines. The claim about pharmaceutical companies paying 'half a million dollars' for drug naming consultants, while a large sum, is within the realm of possibility for specialized branding and regulatory expertise in the pharma industry, where product success hinges on effective and compliant naming. This reflects the high stakes and complexity involved.
Original quote: “Instead, these have to be approved by the FDA who provide this helpful 42-page guide of best practices. [music] Often a big pharma guy like me would pay a drug name consultant like half a million dollars to create and”
Explaining drug naming rules for generic names and stems — straightforward facts. — No Frame (75/100)
At 4:42
He's laying out the actual, specific rules for drug names. No tricks, just the regulations. 😈
Why this score: The speaker is detailing specific FDA or similar regulatory guidelines regarding drug nomenclature, particularly the restrictions on using parts of generic names or common stems. This is presented as factual information about the naming process.
Original quote: “First off, a proprietary name, funnily enough, is not allowed to use either more than [music] three consecutive letters of its generic name, which I do here with Samva, or any generic name stem. [music] Tide is the stem for peptides and glyopeptides.”
Explaining why 'Flexipo' fails due to similarity and misleading abbreviation — clear rules. — No Frame (75/100)
At 4:57
He's showing how names get rejected for sounding too much like others or using forbidden abbreviations. It's all about patient safety. 😈
Why this score: The speaker is explaining two valid reasons for a drug name rejection: phonetic or visual similarity to an existing drug (Lexapro vs. Flexipo) which could lead to medication errors, and the use of a medical abbreviation ('PO' for oral) that is no longer allowed or misleading for the specific drug's administration route. These are standard regulatory concerns.
Original quote: “Two strikes here again. One for being too similar to an existing [music] name, one for the poe at the end. See, flexo is not the same word as lexapro, [music] the already existing anti-depressant, but they're similar enough in sound or scribbled out in the sloppy handwriting of a doctor, that you…”
Citing general guidelines for drug name length — straightforward criteria. — No Frame (75/100)
At 5:34
He's just listing the common length guidelines for drug names. Simple, direct, no hidden agenda. 😈
Why this score: The speaker is stating general, non-binding guidelines for proprietary drug names, specifically regarding syllable and letter count. While not strict legal requirements, these are common industry practices for creating memorable and pronounceable names, often considered by regulatory bodies.
Original quote: “But also because generally a good proprietary name is two to four syllables, which Flexus spray is, but also five to nine letters, which it isn't. Struck down again.”
Illustrating drug name confusion with a real-world 'Dilicor' example — a cautionary tale. — No Frame (75/100)
At 5:41
He's using a real, documented case of drug name confusion causing harm. This isn't a trick; it's a warning. 😈
Why this score: The speaker is providing a concrete example of why drug names are so carefully regulated, using the 'Dilicor' case. This story highlights the critical issue of international drug name confusion leading to medication errors and patient harm, which is a well-known concern in pharmaceutical regulation. The story itself is verifiable through medical incident reports.
Original quote: “How about Dilicor? Well, that's trademarked and is maybe the worst [music] name I could possibly pick because in the US, Dilor is the brand name for the chest pain drug Diltio. But in Serbia, it's a brand name for the heart drug Digazm. Once upon a time, an American traveler refilled his Dilicore…”
Explaining why names implying efficacy are forbidden — a clear regulatory principle. — No Frame (75/100)
At 6:03
He's explaining a core rule: no drug names that promise results. It's a direct statement of regulation. 😈
Why this score: The speaker is accurately stating a fundamental principle of drug naming regulations: names cannot imply efficacy or guarantee results. This is to prevent misleading consumers and ensure that claims about a drug's effectiveness are only made through approved labeling, not through its name. The example 'Lefty Free 24/7' clearly violates this.
Original quote: “How about I just name my drug after what it [music] does? How about something like Lefty Free 24/7 because your left nostril will be free of congestion [music] for a week? Whoop! That's too big of a promise. You can't name a drug in [music] a way that implies or guarantees a result.”
Citing examples of rejected drug names for implying efficacy — real-world applications of the rule. — No Frame (75/100)
At 6:19
He's giving actual examples of names like 'Novo Rapid' and 'Regain' that were rejected for promising too much. This is just how it works. 😈
Why this score: The speaker is providing specific, verifiable examples of drug names ('Novo Rapid' for Novolog and 'Regain' for Rogaine) that were initially proposed but rejected by regulatory bodies (like the FDA) because they implied a specific benefit or outcome. This reinforces the previous point about names not being allowed to guarantee results.
Original quote: “For example, Novalog, an insulin analog, initially wanted to be named Novo Rapid, but even the promise [music] of being fast was too much for the FDA. And Roane, the hair loss treatment, wanted to be Regain at [music] first. And”
Drug names can't have numbers or sound like dosages — that's just common sense, mortals. — No Frame (75/100)
At 6:32
He's laying out the rules for drug naming, and honestly, it's a pretty basic safety measure. No trickery here. 😈
Why this score: The speaker is explaining a logical and necessary regulation in pharmaceutical naming: avoiding numbers that could be confused with dosages. This is a straightforward explanation of a safety protocol, not a manipulative frame. It's a rule designed to prevent actual confusion, which is rare for you lot.
Original quote: “beyond the overpromising of Lefty Free 24/7, you're not supposed to throw numbers in there because people might mistake them for a dosage or just drop [music] them when saying the drug name out loud, leading to more confusion.”
He's trying to game the system with 'Wendozi' — then admits it's too close to 'Wegovy.' Classic mortal optimism. 💀 — Confidence Mismatch (45/100)
At 6:42
He's so sure 'Wendozi' is a winner, then immediately finds a glaring conflict. That's not confidence, that's wishful thinking. 🔥
Why this score: The speaker initially presents 'Wendozi' with a high degree of confidence, listing criteria it supposedly meets ('not trademarked, not a swear word, no promises'). However, he then immediately contradicts this by running it through a hypothetical 'PA tool' and finding it's 'too close to another name' (Wegovy). This rapid shift from confident assertion to immediate self-debunking shows a mismatch between his initial certainty and the actual (hypothetical) evidence.
Original quote: “Okay, how about um Wendozi? To my knowledge, it's [music] not trademarked, not a swear word in another language, makes no promises, three syllables, seven letters. Might we be in business? I don't hear the buzzer. Like the approving bodies did for the generic name, when dozy will get run through…”
See the full analysis with timestamps →